AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Precision DTIL 2025Q2 Earnings Preview Upside Potential on Revenue Growth and EPS Acceleration
Generated by AI AgentAinvestweb
Tuesday, Aug 5, 2025 12:01 pm ET1min read
Forward-Looking Analysis
Precision BioSciences is set to report its Q2 2025 earnings on August 7th. Analysts forecast a decline in earnings by 7.8% per annum, contrasting with an expected annual revenue growth of 5%. Notably, earnings per share (EPS) is anticipated to grow by 18.4% annually, suggesting potential profitability improvements despite overall earnings decline. Recent updates indicate a downward adjustment in price targets alongside an increase in consensus revenue estimates by 47% as of August 11th, reflecting positive market sentiment. This suggests that revenue growth is likely a key driver for future performance. However, Precision BioSciences remains unprofitable, as forecasted over the next three years, with slow revenue growth compared to the US market average. Analyst coverage is low, which may affect the accuracy and reliability of these forecasts.
Historical Performance Review
Precision BioSciences reported a revenue of $29.00 thousand for Q1 2025, with a net loss of $20.57 million. The earnings per share (EPS) stood at a negative $2.21, highlighting continued challenges in profitability. Despite the gross profit aligning with revenue at $29.00 thousand, the company is facing substantial financial hurdles in its pursuit of growth and stability.
Additional News
Precision BioSciences has recently received FDA Rare Pediatric Disease Designation for its PBGENE-DMD program targeting Duchenne Muscular Dystrophy. This development accelerates the PBGENE-DMD project within its organic pipeline, marking a significant stride in its R&D initiatives. Additionally, Precision BioSciences was dropped from the Russell Microcap Growth Index as of June 30th, which might affect its visibility among investors. The company continues to focus on advancing its clinical trials, receiving U.S. FDA Fast Track Designation for PBGENE-HBV, aimed at addressing chronic hepatitis B.
Summary & Outlook
Precision BioSciences shows mixed signals in its financial health, with revenue growth projected at 5% per year and EPS improving at 18.4% per annum. The recent FDA designations offer promising growth catalysts, yet the company remains unprofitable and faces substantial challenges. Its removal from the Russell Microcap Growth Index adds to the risks. However, ongoing advancements in its pipeline may bolster future prospects. The outlook remains neutral, given the combination of potential upside from revenue and EPS growth against persistent earnings challenges and low analyst coverage.
Precision BioSciences is set to report its Q2 2025 earnings on August 7th. Analysts forecast a decline in earnings by 7.8% per annum, contrasting with an expected annual revenue growth of 5%. Notably, earnings per share (EPS) is anticipated to grow by 18.4% annually, suggesting potential profitability improvements despite overall earnings decline. Recent updates indicate a downward adjustment in price targets alongside an increase in consensus revenue estimates by 47% as of August 11th, reflecting positive market sentiment. This suggests that revenue growth is likely a key driver for future performance. However, Precision BioSciences remains unprofitable, as forecasted over the next three years, with slow revenue growth compared to the US market average. Analyst coverage is low, which may affect the accuracy and reliability of these forecasts.
Historical Performance Review
Precision BioSciences reported a revenue of $29.00 thousand for Q1 2025, with a net loss of $20.57 million. The earnings per share (EPS) stood at a negative $2.21, highlighting continued challenges in profitability. Despite the gross profit aligning with revenue at $29.00 thousand, the company is facing substantial financial hurdles in its pursuit of growth and stability.
Additional News
Precision BioSciences has recently received FDA Rare Pediatric Disease Designation for its PBGENE-DMD program targeting Duchenne Muscular Dystrophy. This development accelerates the PBGENE-DMD project within its organic pipeline, marking a significant stride in its R&D initiatives. Additionally, Precision BioSciences was dropped from the Russell Microcap Growth Index as of June 30th, which might affect its visibility among investors. The company continues to focus on advancing its clinical trials, receiving U.S. FDA Fast Track Designation for PBGENE-HBV, aimed at addressing chronic hepatitis B.
Summary & Outlook
Precision BioSciences shows mixed signals in its financial health, with revenue growth projected at 5% per year and EPS improving at 18.4% per annum. The recent FDA designations offer promising growth catalysts, yet the company remains unprofitable and faces substantial challenges. Its removal from the Russell Microcap Growth Index adds to the risks. However, ongoing advancements in its pipeline may bolster future prospects. The outlook remains neutral, given the combination of potential upside from revenue and EPS growth against persistent earnings challenges and low analyst coverage.
Ainvestweb
This internal account is for our software. It'll answer users' questions about subscription products, aiming to boost adoption and retention.
Latest Articles
Regulatory Overreach and the Unintended Consequences: How Blocking Amazon's iRobot Deal Undermined U.S. Robotics Leadership
Dec.20 2025
Is Johnson Controls Overvalued Despite Strong Smart Building Momentum?
Dec.20 2025
Viking Holdings: Assessing the Sustainability of Its Stock Rally Amid Earnings Momentum and Valuation Concerns
Dec.20 2025
Bank ETFs as a Strategic Play for 2026: Capitalizing on a Resurgent U.S. Banking Sector
Dec.20 2025
Garrett Motion's Capital-Return Strategy and Growth Potential in an EV-Driven World
Dec.20 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet